Curriculum Vitaes

Ishii Masaki

  (石井 雅樹)

Profile Information

Affiliation
Faculty of Pharmacy, Department of Pharmaceutical Sciences, Musashino University
Degree
博士(薬学)(東京大学)

J-GLOBAL ID
201701005290675572
researchmap Member ID
B000285329

Research History

 3

Papers

 40
  • Tsuyoshi Yamada, Mari Maeda, Minami Nakagawa, Takashi Yaguchi, Masaki Ishii, Karine Salamin, Christine Pich-Bavastro, Michel Monod
    Antimicrobial Agents and Chemotherapy, Mar 31, 2026  Peer-reviewed
    ABSTRACT The resistance of Trichophyton indotineae to azoles is mainly due to the overexpression of TinCYP51B, resulting from additional copies of this gene in two types of strains (type I and type II). Due to its large size and the significant number of duplicated blocks, whole-genome sequencing has been unable to cover the entire TinCYP51B locus. Through optical genome mapping (OGM), we have successfully determined the copy number of the TinCYP51B gene in the genomes of resistant strains. The TinCYP51B copy number was lower in the type I strains than in the type II strains, while the TinCYP51B expression level was higher in the type I strains. To explain this paradox, we have revealed that polycistronic transcription of multiple TinCYP51B open reading frames (ORFs) alongside monocistronic transcription occurs in type I azole-resistant strains. In contrast, type II strains generated only the transcripts encoding one CYP51B polypeptide. OGM has also revealed that a 970 kb region on chromosome 3 is inverted in type I strains and the azole-susceptible strain TIMM20115, as compared to type II strains and the azole-susceptible strain TIMM20114. This has led to the hypothesis that under azole stress, type I resistant strains originate from susceptible strains such as TIMM20115, which possesses a single TinCYP51B gene. Conversely, it is believed that type II azole-resistant strains evolve from susceptible strains such as TIMM20114, which also has only one TinCYP51B gene. In conclusion, strains of Trichophyton indotineae can be divided into two groups in which a distinct type of resistance has developed.
  • Kazuhiro Mikami, Hiroto Nakajima, Masaki Ishii, Daisuke Yamanaka, Fumiaki Tabuchi, Masashi Muroi, Koichi Makimura, Shinya Ohata, Atsushi Miyashita
    Infection and Immunity, Dec 16, 2025  Peer-reviewed
  • Masaki Ishii, Kazuki Ishikawa, Kazuhiro Mikami, Koji Ichinose, Atsushi Miyashita, Takashi Yaguchi, Tsuyoshi Yamada, Shinya Ohata
    Antimicrobial Agents and Chemotherapy, Nov 5, 2025  Peer-reviewedLead authorCorresponding author
  • Masaki Ishii, Kazuhiro Mikami, Fumiaki Tabuchi, Naho Maruyama, Atsushi Miyashita
    PLOS One, Sep 25, 2025  Peer-reviewedLead authorCorresponding author
  • Masaki Ishii, Shinya Ohata
    Small GTPases, 15(1) 1-8, May 4, 2025  Peer-reviewedInvitedLead authorCorresponding author

Misc.

 10

Major Presentations

 72

Teaching Experience

 11

Professional Memberships

 5

Research Projects

 11

Social Activities

 2